Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels

CONTEXT: The Tongmai Yangxin pill (TMYX) has potential clinical effects on no-reflow (NR); however, the effective substances and mechanisms remain unclear. OBJECTIVE: This study evaluates the cardioprotective effects and molecular mechanisms of TMYX against NR. MATERIALS AND METHODS: We used a myoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ting, Zhang, Yulong, Chen, Manyun, Yang, Pu, Wang, Yi, Zhang, Wei, Huang, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013430/
https://www.ncbi.nlm.nih.gov/pubmed/36896463
http://dx.doi.org/10.1080/13880209.2023.2184481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013430/
https://www.ncbi.nlm.nih.gov/pubmed/36896463
http://dx.doi.org/10.1080/13880209.2023.2184481

Ejemplares similares